FDA ERRED ON BPA REVIEW, PANEL SAYS

The Food and Drug Administration’s (FDA) recent assessment on the safety of bisphenol-A (BPA) was inadequate, according to an October 31 advisory panel review. The committee criticized the agency’s ... Log in to view full article.

Already a subscriber?

Email: REQUIRED

Password: REQUIRED

Forgot your password? Click here to have your password emailed to you.

NOT YET A MEMBER?

Purchase a Membership
with a money-back guarantee
and immediate access